Validation of a Remediation Method for Memory Impairments Through Motor Encoding in Patients With… (NCT07632755) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Validation of a Remediation Method for Memory Impairments Through Motor Encoding in Patients With Alzheimer's Disease
France80 participantsStarted 2026-06-20
Plain-language summary
In France, over 1.5 million people suffer from mild cognitive impairment, often a precursor to Alzheimer's disease (AD), whose global prevalence could reach 153 million by 2050. With no curative treatment available, maintaining patients' autonomy at home is essential to mitigate the negative effects of institutionalization and reduce economic costs. Non-pharmacological approaches, such as cognitive training, have shown potential in stabilizing cognitive functions. Research suggests that motor networks and procedural memory remain relatively preserved in early AD, and bodily engagement during encoding enhances memory. For patients with motor impairments, motor imagery (MI) activates these networks without actual movement. Additionally, dynamic visual cues, like videos, reduce cognitive load compared to static images. This project aims to combine real action, MI, and dynamic visual supports to optimize memory. By validating 120 videos of daily activities, it will assess the impact of action on recall, evaluate MI's effectiveness for patients with mobility limitations, and confirm the superiority of videos over static images. The results could support the development of digital tools, such as serious games, to enhance patients' autonomy and address aging-related challenges.
Who can participate
Age range
60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Patient group: Diagnosis of Alzheimer's disease made by one of the consulting physicians-a neurologist and/or geriatrician (Dubois et al., 2014)-at the early stage, presenting with mild memory impairment of which the patient has been informed
\- MMSE score of 21 or higher
Control group: individuals without a diagnosis of Alzheimer's disease, but meeting the other criteria listed below
* Enrollment in a social security program
* Age 60 or older
* French as a native language
* Consent to participate
Exclusion Criteria:
* Uncorrected visual or hearing impairments
* Language or motor impairments
* Delirium or psychosis.
* Medical treatment affecting vision, language, or motor skills (or participation in a study involving a drug or device that influences cognition).
* Refusal to participate.
* Inability to communicate
* Persons deprived of liberty by a judicial or administrative decision and adults subject to a legal protection measure or unable to express their consent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial focuses on a memory remediation method that uses motor encoding — can you explain what that means in practice, and whether this kind of hands-on memory training approach could be appropriate for where I am in my Alzheimer's diagnosis?
2Since this trial is listed as 'not yet recruiting,' do you know when it's expected to open, and is it worth waiting for compared to memory support programs or cognitive therapies that are available to me right now?
3The trial is measuring free recall scores as its main outcome — can you help me understand what that means for my day-to-day life, and whether improvements in free recall would translate into real, noticeable benefits for me or my family?
4This study includes both Alzheimer's patients and healthy participants — does that tell us anything about what stage of Alzheimer's disease they're looking for, and would my current level of memory impairment make me a realistic candidate to discuss with the research team?
5Because this trial is listed as Phase NA, which often means it's focused on testing a method or technique rather than a drug, what are the known risks of participating in this kind of behavioral or cognitive training study compared to a medication trial?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Free recall score
Timeframe: at 1 week
Trial details
NCT IDNCT07632755
SponsorCentre Hospitalier Universitaire de Saint Etienne